Similar articles

• [Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].

  Mochizuki S, Kiyokawa A, Nagayama Y. Mochizuki S, et al. Clin Calcium. 2005 Jan;15(1):35-42. Clin Calcium. 2005. PMID: 15632471 Review. Japanese.
• [Possible role of RANKL in bone resorption].

  Udagawa N, Nakamura M, Takahashi N. Udagawa N, et al. Nihon Rinsho. 2004 Feb;62 Suppl 2:97-101. Nihon Rinsho. 2004. PMID: 15035104 Review. Japanese. No abstract available.
• [Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)].

  Tomoyasu A, Higashio K. Tomoyasu A, et al. Nihon Rinsho. 2004 Feb;62 Suppl 2:560-5. Nihon Rinsho. 2004. PMID: 15035190 Review. Japanese. No abstract available.
• [Osteoclastogenesis inhibitory factor (OCIF)/OPG].

  Tsuda E, Higashio K. Tsuda E, et al. Nihon Rinsho. 1998 Jun;56(6):1435-9. Nihon Rinsho. 1998. PMID: 9648461 Review. Japanese.
• Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

  Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Yasuda H, et al. Endocrinology. 1998 Mar;139(3):1329-37. doi: 10.1210/endo.139.3.5837. Endocrinology. 1998. PMID: 9492069